Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED
Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
From Cybin Inc.
Via Business Wire
News headline image
Cybin to Acquire Small Pharma Inc.
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for... 
Via Newsfile
Topics Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin to Acquire Small Pharma Inc.
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Renewed ATM Program of up to US$35M
Via Investor Brand Network
News headline image
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Featured in Proactive Interview
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Preparing for CYB003 Capsule Manufacturing for Potential Phase 3 Trial
Via Investor Brand Network
News headline image
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures New US Patent Supporting Its CYB003 Program
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2024 Financial Results, Business Highlights
Via Investor Brand Network
News headline image
Cybin Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Closing of Marketed Public Offering
Via Investor Brand Network
News headline image
Cybin Announces Closing of Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort
Via Investor Brand Network
News headline image
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Overnight Public Offering
Via Investor Brand Network
News headline image
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
News headline image
Cybin Announces Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plans to Participate in Annual Canaccord Genuity Growth Conference
Via Investor Brand Network
News headline image
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Global CRO Partner to Study, Develop CYB003 as Effective MDD Treatment
Via Investor Brand Network
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Significant Milestone in Advancing CYB003 Towards Pivotal Studies
Via Investor Brand Network
News headline image
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.